



NDA 216755/S-001

SUPPLEMENT APPROVAL

Saptalis Pharmaceuticals, LLC
Attention: Rekha Kallam
Sr. Compliance Manager, Quality & Regulatory
45 Davids Drive
Hauppauge, NY 11788

Dear Rekha Kallam:

Please refer to your Supplemental New Drug Application (sNDA) dated December 12, 2023, and received December 13, 2023, pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for LIKMEZ (metronidazole) oral suspension.

This "Changes Being Effected" supplemental new drug application provides for revisions to the approved product labeling based on the results of in-use study that supports extension of the In-Use Period (Study) from 10 days to 60 days after opening of the DP.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the prescribing information, and text for the patient package insert) with the addition of any labeling changes in pending "Changes Being Effected" (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eLIST may be found in the guidance for industry titled *SPL Standard for Content of Labeling Technical Qs and As* at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes, and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

CARTON AND CONTAINER LABELS

Submit final printed carton and container labels that are identical to enclosed carton and container labels, as soon as they are available, but no more than 30 days after they are printed. Please submit these labels electronically according to the guidance for industry *Providing Regulatory Submissions in Electronic Format – Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications*. For administrative purposes, designate this submission “**Product Correspondence – Final Printed Carton and Container Labels for approved NDA 216755/S-001.**” Approval of this submission by FDA is not required before the labeling is used.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Dahlia A. Walters, Regulatory Business Process Manager, at (301) 796 - 8427.

Sincerely,

{See appended electronic signature page}

For:
David Lewis, Ph.D.
Supervisor
Division of Product Quality Assessment XI
Office of Product Quality Assessment II
Office of Pharmaceutical Quality
Center for Drug Evaluation and Research

Enclosure(s):
Content of Labeling
Carton and Container Labeling
Patient Information



Ramesh
Raghavachari

Digitally signed by Ramesh Raghavachari
Date: 5/14/2024 03:23:13PM
GUID: 502d0913000029f375128b0de8c50020